{"name":"A.O. Ospedale Papa Giovanni XXIII","slug":"a-o-ospedale-papa-giovanni-xxiii","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Rilpivirine + darunavir/cobicistat","genericName":"Rilpivirine + darunavir/cobicistat","slug":"rilpivirine-darunavir-cobicistat","indication":"HIV-1 infection in treatment-experienced adults","status":"marketed"},{"name":"stable HAART","genericName":"stable HAART","slug":"stable-haart","indication":"Treatment of HIV-1 infection","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"fludarabine, cyclophosphamide, doxorubicin, rituximab","genericName":"fludarabine, cyclophosphamide, doxorubicin, rituximab","slug":"fludarabine-cyclophosphamide-doxorubicin-rituximab","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"fludarabine, cyclophosphamide, doxorubicin, rituximab","genericName":"fludarabine, cyclophosphamide, doxorubicin, rituximab","slug":"fludarabine-cyclophosphamide-doxorubicin-rituximab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rilpivirine + darunavir/cobicistat","genericName":"Rilpivirine + darunavir/cobicistat","slug":"rilpivirine-darunavir-cobicistat","phase":"marketed","mechanism":"This combination inhibits HIV reverse transcriptase and protease to block viral replication, with cobicistat enhancing darunavir levels.","indications":["HIV-1 infection in treatment-experienced adults"],"catalyst":""},{"name":"stable HAART","genericName":"stable HAART","slug":"stable-haart","phase":"phase_3","mechanism":"Stable HAART refers to a long-term antiretroviral therapy regimen that maintains viral suppression in HIV-1 infected patients.","indications":["Treatment of HIV-1 infection"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}